Compare Target Corporation (TGT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs Viatris Inc — how do they compare? Target Corporation trades at $138.64 (market cap $63.40B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Target Corporation is far larger — about 3.2× Viatris Inc's market cap, and Target Corporation pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| TGT | VTRS | |
|---|---|---|
Market Cap | $63.40B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $17.39 |
52-Week Low | $83.68 | $8.74 |
Enterprise Value | $78.70B | $32.00B |
Dividend Yield | 3.32% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target Corporation (TGT) trades at $138.50, down 0.8% on the day, with a bullish technical outlook supported by moving averages. The company maintains stable revenue near $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent news highlights new product collaborations and institutional buying interest, while analyst consensus leans slightly bullish with a $138.21 price target.
Target's investment case balances solid fundamentals against margin pressures. Opportunities include consistent dividend payments and market share gains in retail, but risks involve competitive pressures and potential consumer spending slowdowns. The stock offers value with a P/E of 18.44 but requires monitoring of net income margin trends.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
